Pradeep Pilania

Pradeep Pilania

Auto-generated profile, based on publicly available information

Pradeep Pilania

Department of Chemistry, Government Science College, Sikar, 332 001, Rajasthan, India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2024 in Current Signal Transduction Therapy
Verified
Journal Article
Closed access
PDF file
PPPradeep Pilania
Pradeep Pilania
SNSisir Nandi
Sisir Nandi
DMDinesh Kumar Meena
Dinesh Kumar Meena
BSBrij K. Sharma
Brij K. Sharma
Regulation of cell proliferation depends on stimulatory and inhibitory factors that act in a coordinated manner in response to external signals. Various agents, including mitogens, growth factors, cytokines, and other external factors, can impact the mitotic cell cycle, resulting in either provoking growth, differentiation, or apoptosis. Many kinases, such as protein kinases, regulate mitotic cell proliferation through normal signalling. One of the major protein kinase family members is cyclin-dependent kinases (CDK), which are responsible for the regulation of cell cycle progression. If the cell cycle-regulatory mechanisms are permanently altered, it can cause abnormal proliferation that leads to neoplasia. This can result in tumour development, where the availability and expression of CDKs become altered, contributing significantly to impaired cell proliferation. Changes like these are often a characteristic of cancer. CDK inhibitors have shown significant clinical benefits in treating various types of tumours in recent years. The output has been achieved by the clinical approvals of particular CDK inhibitors. Researchers have also been studying the proteolysis-targeting chimera (PROTAC) molecule for the last two decades. This molecule uses ubiquitin-mediated proteasome mechanisms to break down specific targets, making it a promising method for targeted protein degradation (TPD). TPD has become a promising therapeutic option for tackling disease-causing proteins that are otherwise challenging to treat using traditional small molecules. This review provides an overview of the state of knowledge and a general understanding of selective or nonselective CDK inhibitors and PROTAC degraders currently under development or clinically approved congeners, focusing on improving cancer therapy.

1 July 2025 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
PPPradeep Pilania
Pradeep Pilania
PSPrithvi Singh
Prithvi Singh
Background: Today, diabetes mellitus (DM) is considered a major global health problem and, especially diabetes mellitus type-2 (T2DM), which accounts for 90-95% of all diabetes cases. Among the novel glucose-lowering agents, dipeptidyl peptidase-4 (DPP-4) inhibitors have been extensively studied in recent years. Objectives: This paper integrates a QSAR study and docking analysis of a series of uracil-based benzoic acid and ester derivatives as novel DPP-4 inhibitors. Methods: The correlation of chemical structure with the biological activity in CP-MLR led to the detection of eleven descriptors from various classes of Dragon descriptors for modeling the activity. The resulting QSAR model has been validated internally and externally using CP-MLR and PLS. Further, the applicability domain analysis revealed the acceptable predictivity of the highest significant model. Results: The best QSAR model displays the r2 Test value of 0.715, Q2 LOO value of 0.797 and Q2 L5O value of 0.809 and this model is used to predict novel compounds with high potency. Further docking study was executed using Autodock 4.2 against DPP-4 protein (PDB ID: 2RGU) that reflects the significant binding potential in newly proposed compounds. Conclusion: From the results, four new congeners have been predicted and validated with good inhibitory activity against DPP-4. Present work reflects that with further optimization of these scaffolds, more selective, potent, and bioavailable DPP-4 inhibitors can be developed for the treatment of T2DM.